Cormedix Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cormedix Inc. on May 29, 2013 (signed May 31, 2013). The filing addresses critical developments regarding the company's continued listing on the NYSE MKT, the scheduling of its 2013 Annual Meeting of Stockholders, and the closing of a recent securities offering.
Key Financial Metrics and Liquidity
- Capital Raise: The company closed a Securities Purchase Agreement on May 30, 2013, selling senior secured convertible notes with a principal amount of $1,500,000 and warrants to purchase up to 1,000,000 shares of common stock.
- Proceeds: Net proceeds received were $1,425,000 (after selling discount, before offering expenses).
- Use of Proceeds: Funds are designated for general corporate purposes, specifically the development and commercialization of Neutrolin, working capital, and capital expenditures.
- Historical Financial Condition: The filing notes that as of December 31, 2012, stockholders' equity was less than $2 million. The company incurred losses from continuing operations and/or net losses in two of its three most recent fiscal years.
Material Changes and Listing Status
The company received notice from the NYSE MKT on May 29, 2013, confirming it made a reasonable demonstration of its ability to regain compliance with Section 1003(a)(i) of the Company Guide by October 20, 2013. Consequently, the listing will continue during this period. This follows previous notices regarding non-compliance with Section 1003(a)(iv) due to substantial losses and impaired financial condition. The company is not eligible for any extension beyond October 20, 2013.
Outlook, Risks, and Corporate Governance
- Delisting Risk: If the company fails to meet compliance standards for Sections 1003(a)(i) and 1003(a)(iv) by the respective deadlines or fails to make consistent progress, the NYSE MKT will initiate delisting proceedings.
- Annual Meeting: The 2013 Annual Meeting is scheduled for July 30, 2013. The record date for stockholders entitled to vote is June 14, 2013.
- Shareholder Approval Required: The company must seek stockholder approval by July 30, 2013, to issue shares upon conversion of notes or exercise of warrants if the aggregate issuance exceeds 2,656,532 shares (20% of outstanding shares as of May 17, 2013).
- Deadlines: Stockholder proposals and director nominations must be received by 5:00 p.m. Eastern time on June 14, 2013.
Investor Verification Checklist
- Verify the company's progress toward regaining compliance with NYSE MKT listing standards by the October 20, 2013 deadline.
- Review the upcoming proxy statement for details on the vote required to approve the issuance of shares exceeding the 20% threshold.
- Monitor the utilization of the $1,425,000 in net proceeds for the development of Neutrolin and working capital needs.
- Confirm the company's financial status relative to the $2 million stockholders' equity requirement and loss history cited in the filing.